#### Supplementary information

## Materials and methods

## γ-irradiation

 $^{137}\text{Cs}$  (0.02 Gy/s; Gammacell 40) was used for  $\gamma\text{-irradiation}.$ 

### **Plasmid constructs**

Two *XPF* disruption constructs, *XPF-hisD* and *XPF-bsr*, were generated from genomic PCR products combined with *hisD*- and *bsr*-selection marker cassettes (Fig. 1 A). Genomic DNA sequences of the *XPF* promoter region were amplified by inverse PCR using primers X-1(+),GGTGCTGGTGCTGAACACGAGC and X-2(-),CCTGATGGAACAGGTCCAGGAAGATCTGGC (for the left arm of the disruption construct) and cloned into the pCR2.1-TOPO vector (Invitrogen). This plasmid was digested with *Hind*III and self-ligated. Genomic DNA sequences of the *XPF* 3' region were amplified by X-3(+),GGTGCTGGTGCTGAACACGAGC and X-4(-),CAGTGGAAACAGAGGCAGGCTTAACATCTC (for the right arm of the disruption construct) and amplified PCR products were cloned into the pCR2.1-TOPO vector (Invitrogen). The 3.4 kb *Eco*RV-*Apa*I fragment from the right arm was cloned into the *Eco*RV and the *Apa*I site of the pCR2.1/XPF-5' arm. The *Eco*RV site between the two arms was used to clone blunt-ended marker-gene cassettes. For the probe used in the Southern blot analysis, the genomic DNA was amplified using primers

X-5(+),GGTGCTGGTGCTGAACACGAGC and

X-6(-),CAGTGGAAACAGAGGCAGGCTTAACATCTC and was digested with *ApaI* to obtain a 2.1 kb fragment. To generate the expression vector,

pCR3-loxP-*GdXPF*/IRES-EGFP-loxP, we amplified *XPF* cDNA using the primers X-7(+),CGCGTCGACATGGCGGCGCTGCTGGAGCACGAGAGCCAG and X-8(-),CGCGGATCCTCATCTTTTGTTTTTTTTTTTTTAGATAGCGC, and inserted the *Sal*I-*Bam*HI fragment of the resulting cDNA between the *Sal*I and *Bam*HI sites of pCR3-*loxP*-MCS-*loxP* (1). Nuclease-deficient *XPF* cDNAs were amplified with primers X-9(+),CGCGGTACCATGGCGGCGCTGCTGGAGCACGAGAGCCAG, X-10(-),CGCGGGCCCTCATCTTTTGTTTTTTTTTTTTTTTTTAGATAGCGC,

D674A(+),CTGCTCAACAGACTATAATAGTGGCTATGCGGGAATTTCGTAGTGA GCTT,

D674A(-),AAGCTCACTACGAAATTCCCGCATAGCCACTATTATAGTCTGTTGAG

CAG,

# D702A(+),GAGCCTGTTACTTTGGAAGTTGGAGCTTACATTTTAACTCCTGATAT CTG, and

D702(-),CAGATATCAGGAGTTAAAATGTAAGCTCCAACTTCCAAAGTAACAGG CTC. The primers

X-11(+),CGCGGATCCTATCCCTATGACGTCCCGGACTATGCATATCCCTATGAC GTCCCGGACTATGCAGGAGGAGGAGGAGGAGGAATGGCGGCGCTGCTGGAGCAC GAGAGCCAG and

X-12(-),CGCGGGCCCTCATCTTTTGTTTTGTTTTTTTTTTTTAGATAGCGC were used to insert an HA-tagged *XPF* cDNA fragment into the pCMV-3Tag vector (Stratagene). The chicken *XPF*, each variant (1 to 5) of *EME1*, and *EME2* cDNA sequences have been submitted to the GenBank database under accession numbers AB085766, AB266761, AB266762, AB266763, AB266764, AB266765, and AB266766, respectively.

#### Identification of proteins that physically interact with Eme1 and Xpf

To identify proteins that are associated with Eme1 and Xpf, we ectopically expressed TAP-tagged GdEme1 and 3x Flag-2xHA-tagged GdXpf in DT40 cells. Cells  $(1 \times 10^9)$  were suspended in lysis buffer (50 mM sodium phosphate at pH 8.0, 0.3 M NaCl, 0.1% NP-40, 5 mM  $\beta$ -mercaptoethanol) with phosphatase inhibitors (10 mM sodium pyrophosphate, 5 mM sodium azide, 10 mM NaF, 0.4 mM sodium orthovanadate, 20 mM  $\beta$ -glycerophosphate) and a complete protease inhibitor (Roche). After sonication (Tomy Seiko, Handy Sonic, UR-20P), the lysate was centrifuged at 15,000 rpm for 10 min at 4° C, after which a supernatant fraction was collected. Anti-Flag M2-beads (SIGMA) were incubated with the supernatant fraction for 2 h at 4° C, and the resin was washed with lysis buffer and then eluted with lysis buffer in the presence of 3x FLAG peptide (SIGMA). Mass-spectrometric identification of proteins was performed as previously described (2).

#### Western blotting and immunoprecipitation

Methods for western blotting and immunoprecipitation were described previously (3). To immunoprecipitate proteins, cells were washed twice with phosphate-buffered saline (PBS) and lyzed with lysis buffer (20 mM Tris-HCl at pH 8.0, 137 mM NaCl, 10% Glycerol, 1% N Nonidet P-40 (NP40) with protease inhibitors (1 mM

phenylmethylsulfonylfluoride (PMSF), 1  $\mu$ g/ml leupeptin, and 1  $\mu$ g/ml aprotinin) and protein phosphatase inhibitors (5 mM sodium fluoride, 1 mM sodium orthovanadate, and 10 mM β-glycerophosphate) for 20 min on ice. After centrifugation, the supernatant was collected and incubated with appropriate antibodies for 2 h at 4° C, and then 20  $\mu$ l of protein G Sepharose (50% slurry) was added. The mixtures were placed on a rotary mixer for 1 h at 4°C. The beads were then washed once with lysis buffer, twice with 0.5 M LiCl/0.1 M Tris-HCl at pH7.5, and once with 10 mM Tris-HCl at pH 7.5, and finally resuspended in Laemmli's sample buffer.

#### **Purification of Recombinant HsXpf-Eme1**

Recombinant baculoviruse was constructed using a Bac-to-Bac system (Invitrogen). Flag-Xpf and Eme1 were co-expressed in HighFive insect cells. Cell monolayers cultured 150 mm dishes were washed twice with ice-cold PBS and lysed with 0.5 ml of ice-cold NP lysis buffer (25 mM Tris-HCl at pH 8.0, 1 mM EDTA, 10% Glycerol, 1% NP40, 1 mM dithiothreitol (DTT), 0.25 mM PMSF, 1× protease inhibitor cocktail [Complete; Roche Diagnostics]) containing 0.3 M NaCl. After 30 min of stirring on ice, the lysate was clarified by centrifugation (20,000g for 20 min), and dialyzed against buffer A (20 mM sodium phosphate at pH 7.8, 1 mM EDTA, 10% Glycerol, 1 mM DTT, and 0.25 mM PMSF). Insoluble materials were removed by centrifugation (20,000g for 30 min). The resulting extract was loaded onto HiPrep-heparin 10/16 column (Amersham Pharmacia Biotech) equilibrated with buffer B (20 mM sodium phosphate at pH 7.8, 0.1 M NaCl, 1 mM EDTA, 10% Glycerol, Triton X-100 0.01%, 1 mM DTT, and 0.25 mM PMSF) containing 0.1 M NaCl. After extensive washing with buffer B containing 0.1 M NaCl, the protein was eluted stepwise with buffer B containing 0.4, and 1 M NaCl, and the Xpf complex was recovered in the 0.4 M NaCl eluate. The haparin-Sepharose 0.4 M NaCl eluate was loaded onto anti-Flag M2 agarose column (Tricorn 10/50; GE Healthcare Bioscience), equilibrated with buffer B containing 0.1 M NaCl. After the column was washed with the same buffer, bound proteins were eluted with 0.1mg/ml Flag peptide. The fractions containing Flag-Xpf were loaded onto a Mono S PC 1.6/5 column that had been connected to a SMART system (GE Healthcare Bioscience) and equilibrated with buffer B containing 0.1 M NaCl. The bound proteins were eluated with a 3-ml gradient of 0.1 to 1 M NaCl in buffer B, where Flag-Xpf was collected from the fractions around 0.4 M NaCl. Flag-Xpf was detected by western blotting, and Emel was confirmed by MS

3

analysis. Finally, the sample was subjected to gel filtration chromatography using a Superdex *200 GL* column (GE Healthcare Bioscience) equilibrated with buffer B containing 0.5 M NaCl.

#### **Generation of Xpf-deficient cells**

Our experimental strategy is described in Supplementary Fig. S6B. Chicken DT40 cells were cultured at 39.5° C in RPMI-1640 medium supplemented with  $10^{-5}$  M  $\beta$ -mercaptoethanol, 10% fetal bovine serum (FBS), and 1% chicken serum. The *XPF-bsr-loxP* targeting construct was transfected into *wild-type* cells harboring pANMerCreMer-*hyg* (4). To excise the *bsr-loxP* in *XPF*<sup>+/-</sup> cells, the cells were exposed to Tamoxifen (TAM) for 3 days and subcloned (*XPF*<sup>+/-</sup>\* clone). The *XPF*<sup>+/-</sup>\* clones were transfected with pCR3-*loxP*-*GdXPF*/IRES-EGFP-*loxP* expression vectors, followed by selection with G418 (2 mg/ml). Among stable transfectants, clones that expressed the greatest amounts of GFP were identified using FACScaliber (Becton Dickinson) and isolated, then exposed to TAM, as previously described. Deletion of the chicken *XPF* transgene was examined using FACScaliber. *XPF*<sup>+/-</sup>\**GdXPF-loxP* clones were transfected with the *XPF-bsr* targeting construct to obtain *XPF*<sup>-/-</sup>*GdXPF-loxP* clones.

## Generation of XPF<sup>-/-</sup>GdXPF-loxP/XRCC3<sup>-/-</sup> cells

Both *XRCC3* alleles were deleted in the *XPF*<sup>-</sup>*GdXPF-loxP* cells using the *XRCC3* targeting construct (5). Deletion of *XRCC3* was confirmed by Southern blot analysis. Deletion of the chicken *XPF* transgene was examined using FACScaliber.

# Generation of *XPF<sup>-/-</sup>GdXPF-loxP* cells expressing RusA, HsXpf-Ercc1, and HsMus81-Eme1

To generate  $XPF^{-}GdXPF$ -loxP cells expressing RusA, mammalian expression vector for RusA-fused nuclear localization signal and GFP (NLS-RusA-GFP) provided by M.C. Whitby was co-transfected with an Eco-gpt marker plasmid into  $XPF^{-}GdXPF$ -loxP cells, followed by selection with 30 µg/ml of mycophenolic acid. Expression of NLS-RusA-GFP was confirmed by western blotting and RT-PCR. To generate  $XPF^{-}GdXPF$ -loxP cells expressing HsXpf-Ercc1, pEYFP-N1-HsXpf provided by L.J. Niedernhofer was co-transfected with a puromycin-resistant-marker plasmid into  $XPF^{-}GdXPF$ -loxP cells, followed by selection with 0.5 µg/ml of puromycin. Expression of EYFP-HsXpf was confirmed by RT-PCR. Next, pCMV6-XL4-ERCC1 purchased from OriGene (Rockville, MD, USA) was co-transfected with *hisD*<sup>R</sup> marker plasmid into *XPF<sup>-/-</sup>GdXPF-loxP* cells expressing EYFP-HsXpf. Expression of HsErcc1 was confirmed by western blotting. To generate *XPF<sup>-/-</sup>GdXPF-loxP* cells expressing HsMus81-Eme1, hMus81 and hEme1 were introduced into *XPF<sup>-/-</sup>GdXPF-loxP* cells by retroviral infection using pMSCV-hMus81 and pMSCV-hEme1. After subcloning, expression of HsMus81-Eme1 was confirmed by RT-PCR.

#### siRNA and antibodies for measurement of chromosome aberrations in HeLa cells.

HeLa cells were maintained in DMEM supplemented with 10% FBS and penicillin-streptomycin. The siRNAs and the antibodies used in this assay were obtained from commercial sources: *MUS81* siRNA; Thermo (L-016143-01-0005) pooled CAGCCCUGGUGGAUCGAUA, GGGUAUACCUGGUGGAAGA, CAGGAGCCAUCAAGAAUAA, GGGAGCACCUGAAUCCUAA, *XPF* siRNA; Thermo (L-019946-00-0005) pooled CCAAACAGCUUUAUGAUUU, GCACCUCGAUGUUUAUAAA, CGGAAGAAAUUAAGCAUGA, UGACAAGGGUACUACAUGA, Anti-Xpf antibody; Abcam (ab17798), Anti-Mus81 antibody; Abcam (ab14387), Anti- $\beta$  actin antibody; SIGMA (A5441). Each primary antibody was used at a 1:1000 dilution. HRP-conjugated mouse IgG secondary antibody (Santa Cruz, sc2314) was used at a 1:5000 dilution.

## siRNA and antibodies for measurement of chromosome aberrations in mouse ES cells.

Mouse *wild-type* (IB10) and *MUS81<sup>-/-</sup>* ES cells were cultured on gelatin-coated dishes in a 1:1 mixture of DMEM and buffalo rat liver conditioned medium, supplemented with 10% FBS, 0.1 mM nonessential amino acids, 50  $\mu$ M  $\beta$ -mercaptoethanol and 500 U ml<sup>-1</sup> leukemia inhibitory factor (6). The siRNAs used in this assay was obtained from commercial sources: *XPF* (*ERCC4*) siRNA; Thermo (L-045003-01-0005) pooled CCACGGAAGAGCAGCGCUA, GGAGCGUGCUUCCGCCAAA, GCUAUGAAGUCUACACGCA, GUAGAGAUUAAGCGUGAAU. Anti-Xpf antibody gifted by R. Kanaar was used at a 1:500 dilution. HRP-conjugated rabbit IgG secondary antibody (Jackson ImmunoResearch Laboratories) was used at a 1:5000 dilution.